Docosapentaenoic acid (n-3 DPA or DPA n-3; 22:5n-3) is a 22-carbon Omega-3 fatty acid with 5 double bonds, positioned metabolically between EPA and DHA. It serves as both an intermediate in omega-3 elongation/desaturation pathways and as an independent precursor for unique Specialized pro-resolving mediators (SPMs), specifically the 13-Series Resolvins (RvT series). n-3 DPA's dual role as metabolic intermediate and bioactive signaling molecule makes it a critical yet often overlooked component of resolution capacity.
Think of n-3 DPA as the middle child in the omega-3 family factory line. EPA (20:5n-3) arrives as raw material, gets elongated by adding two carbons to become n-3 DPA (22:5n-3), which can then be further processed into DHA (22:6n-3) by adding another double bond. But n-3 DPA isn't just sitting passively on the assembly line waiting to become DHA — it's simultaneously running its own side business, producing specialized mediators (the RvT series) that the other family members can't make.
Imagine a factory worker who's supposed to pass parts down the line, but while waiting, they craft custom tools nobody else can make. Sometimes the assembly line to DHA gets backed up (when desaturase enzymes are sluggish), and n-3 DPA accumulates like inventory in a warehouse. That's not necessarily bad — it means more raw material for those unique RvT mediators. The factory analogy captures the key insight: n-3 DPA has value both as a transition state AND as an end product, making it uniquely versatile in the resolution machinery.
n-3 DPA synthesis occurs through the omega-3 elongation pathway:
EPA → n-3 DPA → DHA cascade:
- EPA (20:5n-3) enters the endoplasmic reticulum
- Elongase enzymes (ELOVL2, ELOVL5) add two carbons → 22:5n-3 (n-3 DPA)
- Delta-6 Desaturase (rate-limiting) adds 6th double bond → 24:6n-3
- Beta-oxidation in peroxisomes removes two carbons → DHA (22:6n-3)
Bottleneck: When delta-6 desaturase is impaired (age, insulin resistance, genetic polymorphisms, inflammation, zinc/magnesium deficiency), n-3 DPA accumulates.
n-3 DPA undergoes enzymatic oxygenation to produce 13-Series Resolvins (RvTs):
graph TD
A["n-3 DPA 22:5n-3"] --> B[12-LOX]
A --> C[15-LOX]
A --> D[COX-2]
B --> E[13S-hydroxy-DPA]
C --> F[17S-hydroxy-DPA]
D --> G[13R-hydroxy-DPA aspirin-triggered]
E --> H[RvT1-4 series]
F --> I[Additional RvT mediators]
G --> J[AT-RvTs aspirin-triggered resolvins]
H --> K[Receptor Activation]
I --> K
J --> K
K --> L[GPR32 DRV1]
K --> M[GPR18 DRV2]
K --> N[ALX-FPR2]
L --> O[Resolution Effects]
M --> O
N --> O
O --> P[Enhanced efferocytosis]
O --> Q[Reduced neutrophil infiltration]
O --> R["Macrophage reprogramming M1→M2"]
O --> S[Tissue regeneration signals]
Key enzymatic conversions:
- 12-LOX (ALOX12) → 13S-hydroxy-DPA → RvT1, RvT2, RvT3, RvT4
- 15-LOX (ALOX15) → 17S-hydroxy-DPA → additional RvT mediators
- COX-2 acetylation (aspirin-triggered) → 13R-epimers (AT-RvTs)
RvT mediators bind distinct G-protein coupled receptors:
- GPR32 (DRV1) — primary receptor for RvTs → cAMP modulation, Efferocytosis enhancement
- GPR18 (DRV2) — neutrophil chemotaxis inhibition
- ALX-FPR2 — cross-reactive with multiple SPMs, broad anti-inflammatory signaling
Downstream signaling cascade:
RvT-receptor binding → Gαi/o activation → cAMP reduction → PKA inhibition → reduced NF-κB nuclear translocation → decreased pro-inflammatory gene transcription (IL-1β, TNF-α, IL-6) + increased resolution genes (annexin A1, lipoxin receptors)
RvTs undergo dehydrogenation and beta-oxidation:
- 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) → oxidation to less active keto-forms
- Further beta-oxidation → eventual clearance
- Half-life: 10-30 minutes (similar to other SPMs)
Patient populations where n-3 DPA status matters:
- Resolution-resistant chronic inflammation — patients supplementing EPA/DHA without clinical improvement may have impaired delta-6 desaturase, causing n-3 DPA depletion and RvT deficiency
- Elderly patients — aging reduces desaturase activity; n-3 DPA may accumulate but still produce resolution mediators when EPA→DHA conversion fails
- Insulin resistance/Type 2 Diabetes — high insulin inhibits delta-6 desaturase; n-3 DPA levels may be paradoxically elevated but functional if RvT synthesis is intact
- Inflammatory bowel disease — RvT mediators show distinct efficacy in mucosal healing compared to EPA/DHA-derived SPMs
- Neurodegenerative conditions — n-3 DPA crosses blood-brain barrier; local RvT synthesis may contribute to neuroinflammation resolution
5 plus 2 metamodel: n-3 DPA exemplifies evolutionary mismatch in modern lipid metabolism. Ancestral diets rich in marine mammals (seal, whale) provided direct n-3 DPA, bypassing the need for efficient EPA→DHA conversion. Modern diets lack n-3 DPA entirely, placing full burden on endogenous synthesis at a time when desaturase enzymes are impaired by hyperinsulinemia and chronic Low-Grade Inflammation.
Selfish Immune System: The immune system may sequester n-3 DPA preferentially when resolution mediator synthesis is prioritized over structural membrane incorporation (as DHA). This creates competition with brain and retina for omega-3 resources.
¶ Clinical Thresholds and Biomarkers
- Optimal n-3 DPA levels: 0.5-1.5% of total plasma fatty acids (similar range to EPA)
- n-3 DPA:EPA ratio >0.3 suggests impaired desaturase activity (accumulation of intermediate)
- n-3 DPA depletion (<0.3%) in context of adequate EPA/DHA indicates rapid conversion OR inadequate substrate
- RvT metabolite profiling (specialized lipidomics) can assess functional capacity but not clinically available
- Direct n-3 DPA supplementation: Seal oil (15-25% n-3 DPA), certain fish oils (mackerel, herring ~2-4% n-3 DPA) provide direct source, bypassing conversion pathway
- Support endogenous synthesis:
- Address insulin resistance to restore delta-6 desaturase
- Zinc (15-30 mg/day) and Magnesium (400-600 mg/day) as desaturase cofactors
- Reduce competing pathway substrates (excess linoleic acid/omega-6)
- Aspirin co-administration: Low-dose aspirin (75-100 mg/day) triggers COX-2 acetylation, producing AT-RvTs with potentially enhanced potency
- Address resolution enzyme deficiencies: Ensure adequate Vitamin D (25(OH)D >75 nmol/L), B vitamins (B6, folate, B12) for optimal lipoxygenase function
When to suspect n-3 DPA insufficiency:
- Adequate omega-3 intake but poor inflammatory resolution
- Elevated CRP (>3 mg/L) despite EPA/DHA supplementation
- Impaired wound healing or delayed recovery from acute inflammation
- Persistent neutrophil activation (elevated Calprotectin, neutrophil-lymphocyte ratio >3)
- Molecular structure: 22 carbons, 5 double bonds at positions 7, 10, 13, 16, 19 from methyl end
- Typical plasma concentration: 0.5-1.2% of total fatty acids (lower than EPA and DHA)
- Dietary sources: Seal oil (6-9%), herring (3-4%), mackerel (2-3%), salmon (1-2%)
- Conversion efficiency: ~15-20% of EPA converts to n-3 DPA; only 5-10% of n-3 DPA proceeds to DHA in adults
- Age-related changes: n-3 DPA accumulates with age as delta-6 desaturase activity declines 40-60% after age 60
- RvT potency: Nanomolar concentrations (1-100 nM) effective for resolution signaling
- Receptor specificity: RvTs show 10-fold higher affinity for GPR32 than EPA-derived resolvins
- Half-life in plasma: 8-12 hours (fatty acid form); 10-30 minutes (SPM metabolites)
- Tissue distribution: Enriched in immune cells (macrophages, neutrophils), moderate in brain, low in adipose
- Clinical improvement threshold: Increasing n-3 DPA from <0.3% to >0.8% of total fatty acids associated with improved resolution markers in small studies
- EPA — direct precursor; EPA undergoes elongation via ELOVL enzymes to form n-3 DPA
- DHA — downstream product; n-3 DPA can be desaturated and beta-oxidized to form DHA, though conversion is often rate-limited
- Delta-6 Desaturase — rate-limiting enzyme in DHA synthesis; when impaired, n-3 DPA accumulates as metabolic intermediate
- 13-Series Resolvins — unique SPM family (RvT1-4) produced exclusively from n-3 DPA via 12-LOX and 15-LOX pathways
- Specialized pro-resolving mediators (SPMs) — n-3 DPA serves as distinct precursor class, complementing EPA-derived E-series and DHA-derived D-series resolvins
- Resolvins — broader family of resolution mediators; n-3 DPA contributes the T-series (RvT) subfamily
- Omega-3 fatty acids — n-3 DPA is the intermediate-length omega-3, positioned between EPA (20C) and DHA (22C)
- 12-LOX — primary enzyme converting n-3 DPA to 13S-hydroxy-DPA, initiating RvT biosynthesis
- 15-LOX — alternative lipoxygenase pathway producing 17S-hydroxy-DPA and additional RvT variants
- COX-2 — when acetylated by aspirin, produces R-epimer RvTs with distinct receptor binding profiles
- Efferocytosis — RvTs enhance macrophage clearance of apoptotic neutrophils via GPR32-mediated signaling
- Resolution of inflammation — n-3 DPA-derived mediators activate distinct resolution pathways, expanding therapeutic options beyond EPA/DHA
- Insulin resistance — impairs delta-6 desaturase, causing n-3 DPA accumulation; paradoxically may preserve RvT synthesis capacity
- Type 2 Diabetes — altered omega-3 metabolism with characteristic n-3 DPA:DHA ratio elevation
- GPR32 — primary receptor for RvT mediators, coupling to Gαi to reduce inflammation and enhance resolution
- GPR18 — secondary RvT receptor mediating neutrophil chemotaxis inhibition
- ALX-FPR2 — promiscuous SPM receptor binding multiple resolution mediators including RvTs
- Neutrophil — primary target cell for RvT-mediated chemotaxis inhibition and apoptosis facilitation
- Lipid mediator class switching — transition from pro-inflammatory eicosanoids to pro-resolving RvTs represents metabolic reprogramming
- Aspirin-triggered resolvins — aspirin acetylation of COX-2 produces 13R-epimer RvTs with enhanced stability
- Chronic inflammation — inadequate RvT production may perpetuate unresolved inflammation despite adequate EPA/DHA
- Zinc — essential cofactor for delta-6 desaturase; deficiency impairs n-3 DPA→DHA conversion
- Magnesium — cofactor for elongase and desaturase enzymes in omega-3 metabolism
- Macrophage Polarization — RvTs promote M2 macrophage phenotype via GPR32-mediated cAMP modulation
- Inflammatory bowel disease — RvT mediators show distinct mucosal healing effects compared to other SPM classes
- Vitamin D — regulates lipoxygenase expression; deficiency impairs RvT biosynthesis capacity